Rafferty Asset Management LLC Buys 119,257 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Rafferty Asset Management LLC increased its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDXFree Report) by 42.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 403,381 shares of the company’s stock after acquiring an additional 119,257 shares during the quarter. Rafferty Asset Management LLC owned about 0.48% of Syndax Pharmaceuticals worth $8,717,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Arizona State Retirement System increased its holdings in shares of Syndax Pharmaceuticals by 5.3% in the fourth quarter. Arizona State Retirement System now owns 16,511 shares of the company’s stock worth $357,000 after acquiring an additional 835 shares in the last quarter. New York State Common Retirement Fund raised its holdings in Syndax Pharmaceuticals by 3.6% during the 3rd quarter. New York State Common Retirement Fund now owns 30,825 shares of the company’s stock worth $448,000 after buying an additional 1,080 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Syndax Pharmaceuticals by 9.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,126 shares of the company’s stock valued at $305,000 after buying an additional 1,162 shares in the last quarter. CWM LLC increased its position in shares of Syndax Pharmaceuticals by 415.3% during the fourth quarter. CWM LLC now owns 1,685 shares of the company’s stock worth $36,000 after acquiring an additional 1,358 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its holdings in shares of Syndax Pharmaceuticals by 158.3% during the fourth quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock worth $53,000 after acquiring an additional 1,496 shares during the period.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX opened at $19.21 on Thursday. The firm has a 50 day simple moving average of $21.38 and a two-hundred day simple moving average of $21.09. Syndax Pharmaceuticals, Inc. has a one year low of $11.22 and a one year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDXGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.11. During the same period last year, the firm posted ($0.59) EPS. On average, analysts expect that Syndax Pharmaceuticals, Inc. will post -3.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SNDX has been the topic of a number of recent research reports. Stifel Nicolaus lifted their target price on Syndax Pharmaceuticals from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $34.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, May 21st. HC Wainwright restated a “buy” rating and set a $41.00 price objective on shares of Syndax Pharmaceuticals in a report on Thursday, May 9th. Finally, Citigroup reduced their target price on shares of Syndax Pharmaceuticals from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $34.42.

Get Our Latest Stock Analysis on Syndax Pharmaceuticals

About Syndax Pharmaceuticals

(Free Report)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

Further Reading

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.